

Biocept Inc

10:34 08 Jan 2020

Biocept wins US Patent for its liquid biopsy cancer testing technology; shares jump

Biocept Inc (NASDAQ:BIOC), a developer of liquid biopsy tests that detect and isolate cancer biomarkers, announced Wednesday that it has been awarded a US Patent for its technology.

Investors cheered the patent award, sending the stock up nearly 20% to \$0.44 a share in New York.

The newly issued patent -- DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS -- covers devices for the detection of cells of interest, including circulating tumor cells (CTCs), that are shed into the bloodstream by solid tumors where an antibody, or mixture of antibodies, and any solid surface are used for cell capture, detection, and analysis.

The patent includes any biological sample type of interest and includes the use of single antibodies or cocktails of antibodies, Biocept said in a statement.

READ: Biocept unveils latest liquid biopsy test to identify cancer-associated proteins

"The granting of this patent broadly expands Biocept's intellectual property estate for capturing and detecting cells of interest using antibodies, which combines nicely with our patented microchannel and cell staining platforms," said Lyle Arnold, Biocept's chief scientific officer.

"This allowed patent also interfaces very well with our other patented technologies that include a blood collection tube, and ctDNA analysis platforms for aiding patient treatment decisions."

The company said the device claims covered by the patent broadly apply to the use of antibodies for the capture and detection of target cells of interest on any solid surface. This includes CTCs, as well as any other cell of interest.

Capturing very rare cells

Combined with the company's patented microchannel and cell staining platform technologies, Biocept said it now has patented the capability to enable the capture of any cell of interest, including very rare cells, that may be present in blood and any other biological sample type.

"We continue to lead the way in innovation for liquid biopsy technology, and this latest patent demonstrates our leadership in creating new methodologies to identify potential cancer cells, or cells of any type for that matter," said CEO Michael Nall.

"We are very proud of our innovations in the industry and look forward to sharing future applications for this patented technology to capture cellular targets in biological fluids, even when found in very small quantities."

Biocept, based in San Diego, has won more than 30 patents worldwide stemming from its liquid biopsy technology and

Price: 0.2842

Market Cap: \$30.89 m

1 Year Share Price Graph



April 2019 October 2019 April 2020

Share Information

Code: BIOC

Listing: NASDAQ

52 week	High	Low
	2.11	0.2118

Sector: Medical technology & services

Website: biocept.com

Company Synopsis:

Biocept, Inc. is a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both CTCs and in plasma (ctDNA).

action@proactiveinvestors.com

commercial-testing platforms.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).